Alto Neuroscience, Inc. (ANRO)
USD 3.64
(-3.96%)
USD 3.64
(-3.96%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | 210 Thousand |
| Cost of Revenue | 373 Thousand | 342 Thousand | 145 Thousand |
| Gross Profit | -373 Thousand | -342 Thousand | 65 Thousand |
| Operating Expenses | 37.8 Million | 28.85 Million | 12.12 Million |
| Selling, General and Administrative Expenses | 7.51 Million | 5.16 Million | 3.75 Million |
| Research and Development Expenses | 30.29 Million | 23.68 Million | 8.36 Million |
| Other Expenses | - | - | - |
| Cost and Expenses | 37.8 Million | 29.19 Million | 12.26 Million |
| Operating Income | -37.8 Million | -29.19 Million | -12.05 Million |
| Interest Expense | 1.37 Million | - | - |
| Income Tax Expense | - | - | - |
| Earnings before Tax | -36.3 Million | -27.71 Million | -9.18 Million |
| Net Income | -36.3 Million | -27.71 Million | -9.18 Million |
| Earnings Per Share Basic | -1.35 | -1.08 | -0.36 |
| Earnings Per Share Diluted | -1.35 | -1.08 | -0.36 |
| Weighted Average Shares Outstanding | 26.88 Million | 25.57 Million | 25.57 Million |
| Weighted Average Shares Outstanding (Diluted) | 26.88 Million | 25.57 Million | 25.57 Million |
| Gross Margin | - | - | 0.31 |
| EBIT Margin | - | - | -56.72 |
| Profit Margin | - | - | -43.75 |
| EBITDA | -34.56 Million | -27.36 Million | -9.04 Million |
| Earnings Before Tax Margin | - | - | -57.41 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 372 Thousand | - | - | - |
| Cost of Revenue | 100 Thousand | 97 Thousand | 92 Thousand | 373 Thousand | - | 100 Thousand |
| Gross Profit | -100 Thousand | -97 Thousand | 280 Thousand | -373 Thousand | - | -100 Thousand |
| Operating Expenses | 18.24 Million | 14.28 Million | 11.67 Million | 37.43 Million | 9.71 Million | 9.02 Million |
| Selling, General and Administrative Expenses | 5.05 Million | 4.33 Million | 2.02 Million | - | 1.75 Million | 1.95 Million |
| Research and Development Expenses | 13.18 Million | 9.95 Million | 9.64 Million | - | 7.96 Million | 7.07 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 18.34 Million | 14.38 Million | 11.76 Million | 37.8 Million | 9.71 Million | 9.12 Million |
| Operating Income | -18.34 Million | -14.38 Million | -11.76 Million | -37.8 Million | -9.71 Million | -9.12 Million |
| Interest Expense | 347 Thousand | 346 Thousand | 356 Thousand | 1.37 Million | 363 Thousand | 327 Thousand |
| Income Tax Expense | -1.00 | - | -363 Thousand | - | 363 Thousand | - |
| Earnings before Tax | -16.03 Million | -13.41 Million | -11.21 Million | -36.3 Million | -9.14 Million | -8.66 Million |
| Net Income | -16.03 Million | -13.41 Million | -11.21 Million | -36.3 Million | -9.14 Million | -8.66 Million |
| Earnings Per Share Basic | -0.59 | -0.50 | -0.42 | - | -0.34 | -0.32 |
| Earnings Per Share Diluted | -0.59 | -0.50 | -0.42 | - | -0.34 | -0.32 |
| Weighted Average Shares Outstanding | 26.95 Million | 26.88 Million | 26.88 Million | 26.88 Million | 26.88 Million | 26.88 Million |
| Weighted Average Shares Outstanding (Diluted) | 26.95 Million | 26.88 Million | 26.88 Million | 26.88 Million | 26.88 Million | 26.88 Million |
| Gross Margin | - | - | 0.75 | - | - | - |
| EBIT Margin | - | - | -31.38 | - | - | - |
| Profit Margin | - | - | -30.15 | - | - | - |
| EBITDA | -18.24 Million | -14.28 Million | -11.67 Million | - | -8.92 Million | -9.02 Million |
| Earnings Before Tax Margin | - | - | -31.63 | - | - | - |
FCH
CROX
OFG
MOPHY
BIOT
GTY